Found: 12
Select item for more details and to access through your institution.
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- Journal of the Peripheral Nervous System, 2022, v. 27, n. 2, p. 159, doi. 10.1111/jns.12487
- By:
- Publication type:
- Article
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
- Published in:
- Journal of the Peripheral Nervous System, 2020, v. 25, n. 3, p. 230, doi. 10.1111/jns.12402
- By:
- Publication type:
- Article
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 72, doi. 10.1111/jns.12303
- By:
- Publication type:
- Article
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 48, doi. 10.1111/jns.12302
- By:
- Publication type:
- Article
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
- Published in:
- Journal of the Peripheral Nervous System, 2017, v. 22, n. 2, p. 149, doi. 10.1111/jns.12204
- By:
- Publication type:
- Article
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
- Published in:
- Journal of the Peripheral Nervous System, 2013, v. 18, n. 2, p. 130, doi. 10.1111/jns5.12017
- By:
- Publication type:
- Article
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 839, doi. 10.1002/psp4.12647
- By:
- Publication type:
- Article
Homocysteine in Cerebrovascular Disease: an Independent Risk Factor for Subcortical Vascular Encephalopathy.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2001, v. 39, n. 8, p. 721
- By:
- Publication type:
- Article